Category: District of Delaware
-
Nvidia, Western Digital among defendants as vertical chip designer MonolithIC 3D expands multi-district litigation campaign
After filing several U.S. infringement suits in recent months, MonolithIC 3D has just fired off another salvo involving a new set of semiconductor design patents.
-
10x settles with Curio, immediately goes on to sue Element Biosciences over next-generation sequencing patents
In the next-generation sequencing space, 10x Genomics has settled its litigation with Curio Biosciences, just before filing a new patent infringement lawsuit against Element Biosciences in Delaware.
-
FedEx can fight another day in Qualcomm dispute, as Federal Circuit considers IPR real-parties-in-interest
The USPTO withdrew its initial defense of the PTAB’s refusal of FedEx’s arguments around real parties in interest.
-
Pfizer settles with three Vyndamax generic challengers mid-trial, extends exclusivity, presumably through pay-for-delay
Pfizer has quickly reached a settlement with Cipla, Hikma, and Dexcel during a five-day bench trial in Delaware, ending the dispute and extending its effective monopoly.
-
CureVac sues Moderna in Delaware over Spikevax patents, seeking treble damages but no injunction
CureVac sues Moderna for treble damages but not an injunction over 10 patents related to Spikevax. The case adds to broader post-COVID mRNA patent battles.
-
PTAB invalidates Trina Solar’s TOPCon patents, ending parallel U.S. proceedings against Canadian Solar
The PTAB invalidated all claims of two TOPCon patents asserted by Trina Solar against Canadian Solar. The rulings effectively halt the parallel U.S. proceedings, leaving appeal as the only path forward.
-
Apple settles wide-angle camera patent infringement dispute in District of Delaware after successfully invoking “single-means” doctrine
Apple has settled two parallel actions brought by Canada’s Immervision over the alleged infringement of the latter’s wide-angle camera-related patents, bringing the companies’ five-year dispute to an end.
-
Novo Nordisk settles U.S. semaglutide patent infringement dispute, but denied Indian interim injunction again
While Novo Nordisk has struck an agreement with U.S. telehealth platform Hims & Hers to sell Ozempic and Wegovy, the Delhi High Court has once again denied its request for an interim injunction against Dr. Reddy’s Laboratories to block its sales of semaglutide products after its patent expires in 10 days.
-
Moderna, Genevant, Arbutus settle global mRNA patent infringement dispute
Moderna could have to pay up to $2.25 billion as part of the settlement agreement, but remains confident it will close 2026 with up to $5 billion in cash and cash equivalents as a result of the deal.